ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - תרחיף להזרקה - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of ten years onwards.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin; pertussis toxoid (pt); tetanus toxoid - תרחיף להזרקה - diphtheria toxoid nlt 30 iu; tetanus toxoid nlt 40 iu; pertactin 8 mcg / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml - bacterial and viral vaccines, combined - infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either dtpa vaccine or diphtheria, tetanus and whole-cell pertussis (dtpw) vaccine. active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.

ישראל - עברית - Ministry of Health

tec-o-pharm libra ltd - רופא - התקן תוך רחמי

ישראל - עברית - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b

ישראל - עברית - Ministry of Health

sanofi israel ltd - conjugated to tetanus protein; diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; pertussis toxoid (pt); polio type i (mohoney); polio type ii ( m.e.f.1); polio type iii (saukett); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - polio type iii (saukett) 32 du / 0.5 ml; polio type ii ( m.e.f.1) 8 du / 0.5 ml; polio type i (mohoney) 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid 40 iu / 0.5 ml; diphtheria toxoid 30 iu / 0.5 ml; haemophilus influenzae type b polysaccharide 10 mcg / 0.5 ml; conjugated to tetanus protein 18-30 mcg / 0.5 ml - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

ישראל - עברית - Ministry of Health

gsk consumer healthcare, israel ltd - chlorhexidine digluconate - תמיסה - chlorhexidine digluconate 0.2 %w/v - chlorhexidine - chlorhexidine - antibacterial solution for the disinfection of the mouth.1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.

ישראל - עברית - Ministry of Health

gsk consumer healthcare, israel ltd - calcium carbonate - טבליות לעיסות - calcium carbonate 750 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).